TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that the Superior Court of Justice – Ontario (Commercial List) (the “Court”) has fully dismissed the statement of claim (CV-25-00742450-0000) (the “Claim”) issued by Apollo Technology Capital Corporation (“Apollo”), Nobul Technologies Inc. (“Nobul”), and Regan McGee (together w

PRESS RELEASE, 11/14/2025, 10:00 AM EST Biocartis Showcases Growing Impact of Idylla™ Platform at AMP 2025 Multiple abstracts and a corporate workshop highlight Idylla™’s growing role in oncology diagnostics Itasca, IL, United States, 14 November 2025 – Biocartis, an innovative molecular diagnostics company, is pleased to announce that multiple abstracts highlighting the growing adoption of the Idylla™ Platform in research and clinical collaborations are being presented at the Association f

A new survey and associated campaign are part of a recent spate of initiatives focused on health equity in rural areas. An Association of Black Cardiologists (ABC) survey has uncovered a widespread gap in cardiovascular health awareness among under-resourced regions of and communities in the U.S., pointing to the need for an educational campaign in these “cardiology deserts.”Amgen put up seed sponsorship support for the “Every Heart Counts: ABC Cardiology Deserts Campaign” to help t

The European Medicines Agency’s human medicines committee (CHMP) recommended the approval of a Sanofi type 1 diabetes drug, Eli Lilly’s oral SERD for a certain type of breast cancer, and three other new therapies. While the European Commission has the final authority over new drug approvals, it typically follows CHMP’s recommendations. Sanofi acquired its diabetes drug Tzield, or teplizumab, in its 2023 buyout of Provention Bio. The drug was approved in the US in 2022, after showing it could del

On LEAP Day, clinicians are urged to complete a simple three-minute foot assessment and refer at-risk patients to podiatric specialists. NEW CANAAN, Conn., Nov. 14, 2025 /PRNewswire/ -- In recognition of Diabetes Awareness Month, Arche Healthcare is reaffirming November 14 as LEAP Day ( Lower Extremity Amputation Prevention) a national call to action that shines a light on the growing public-health crisis of diabetes-related lower-extremity amputations and mobilizes clinicians to act. On LE

BOCA RATON, Fla., Nov. 14, 2025 /PRNewswire/ -- BodyLogicMD, a leading provider of bioidentical hormone replacement therapy (BHRT), integrative medicine and weight loss treatment, announced it completely supports the recommendation to remove black box warnings on certain forms of estrogen used to treat menopause symptoms. Data from an old government study on women's health, known as the Women's Health initiative (WHI), led to conclusions that hormone therapy was linked to an increased risk of se

After reviewing Lundbeck’s proposal, Avadel’s board of directors has “determined in good faith” that the offer will likely be considered superior under its current agreement with Alkermes. Just as the dust had settled around Pfizer’s brief Metsera bidding war with Novo Nordisk, another planned biopharma acquisition has been thrust into uncertainty by a surprise counteroffer.Lundbeck is cutting in on Alkermes' proposed purchase of its Irish biopharma compatriot Avadel Pharmaceuticals, rev

None In this week’s episode of "The Top Line," we take a deep dive into the top-line performance of the biopharma industry in the third quarter. After a slow start to the year, U.S. drugmakers in particular have recovered, led by Eli Lilly. We examine which companies are hot and which are not. We also look at trends that emerged in the third quarter, such as the shortfall in vaccine sales, especially in the U.S., and companies’ sales projections for the rest of the year.Fierce Pharm

LEXINGTON, Mass., Nov. 14, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that Curis will report emavusertib and BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) in three presentations and preclinical data on emavusertib in an oral presentation at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) on

Bagsværd, Denmark, 14 November 2025 - Today, Novo Nordisk A/S held its Extraordinary General Meeting, which was convened to elect new members of the Board of Directors. At the Extraordinary General Meeting, Helge Lund (chair), Henrik Poulsen (vice chair) and the Board members Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law and Martin Mackay stepped down from the Board of Directors. Resolutions adopted at the Extraordinary General Meeting Elections All elections are for the period